428 related articles for article (PubMed ID: 29959725)
1. Use of Esophageal pH Monitoring to Minimize Proton-Pump Inhibitor Utilization in Patients with Gastroesophageal Reflux Symptoms.
Triadafilopoulos G; Zikos T; Regalia K; Sonu I; Fernandez-Becker NQ; Nguyen L; Nandwani MCR; Clarke JO
Dig Dis Sci; 2018 Oct; 63(10):2673-2680. PubMed ID: 29959725
[TBL] [Abstract][Full Text] [Related]
2. Value of pH Impedance Monitoring While on Twice-Daily Proton Pump Inhibitor Therapy to Identify Need for Escalation of Reflux Management.
Gyawali CP; Tutuian R; Zerbib F; Rogers BD; Frazzoni M; Roman S; Savarino E; de Bortoli N; Vela MF; Sifrim D
Gastroenterology; 2021 Nov; 161(5):1412-1422. PubMed ID: 34270955
[TBL] [Abstract][Full Text] [Related]
3. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
[TBL] [Abstract][Full Text] [Related]
4. Postreflux swallow-induced peristaltic wave index and nocturnal baseline impedance can link PPI-responsive heartburn to reflux better than acid exposure time.
Frazzoni L; Frazzoni M; de Bortoli N; Tolone S; Furnari M; Martinucci I; Bertani H; Marchi S; Conigliaro R; Fuccio L; Savarino V; Savarino E
Neurogastroenterol Motil; 2017 Nov; 29(11):. PubMed ID: 28543861
[TBL] [Abstract][Full Text] [Related]
5. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
[TBL] [Abstract][Full Text] [Related]
6. Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo
Schey R; Alla SP; Midani D; Parkman HP
Rev Gastroenterol Mex; 2017; 82(4):277-286. PubMed ID: 28385467
[TBL] [Abstract][Full Text] [Related]
7. Value of 96-hour ambulatory esophageal pH monitoring in the assessment of patients with refractory acid reflux symptoms and their response to anti-reflux diet.
Triadafilopoulos G; Kamal A; Clarke JO
Dis Esophagus; 2023 Jul; 36(7):. PubMed ID: 36567531
[TBL] [Abstract][Full Text] [Related]
8. ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?
Azzam RS
Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):85-91. PubMed ID: 30304291
[TBL] [Abstract][Full Text] [Related]
9. Most Patients With Gastroesophageal Reflux Disease Who Failed Proton Pump Inhibitor Therapy Also Have Functional Esophageal Disorders.
Abdallah J; George N; Yamasaki T; Ganocy S; Fass R
Clin Gastroenterol Hepatol; 2019 May; 17(6):1073-1080.e1. PubMed ID: 29913281
[TBL] [Abstract][Full Text] [Related]
10. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor?
Hemmink GJ; Bredenoord AJ; Weusten BL; Monkelbaan JF; Timmer R; Smout AJ
Am J Gastroenterol; 2008 Oct; 103(10):2446-53. PubMed ID: 18684197
[TBL] [Abstract][Full Text] [Related]
11. AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review.
Yadlapati R; Gyawali CP; Pandolfino JE;
Clin Gastroenterol Hepatol; 2022 May; 20(5):984-994.e1. PubMed ID: 35123084
[TBL] [Abstract][Full Text] [Related]
12. Algorithmic approach to patients presenting with heartburn and epigastric pain refractory to empiric proton pump inhibitor therapy.
Roorda AK; Marcus SN; Triadafilopoulos G
Dig Dis Sci; 2011 Oct; 56(10):2871-8. PubMed ID: 21512760
[TBL] [Abstract][Full Text] [Related]
13. The effect of endoscopic fundoplication and proton pump inhibitors on baseline impedance and heartburn severity in GERD patients.
Rinsma NF; Farré R; Bouvy ND; Masclee AA; Conchillo JM
Neurogastroenterol Motil; 2015 Feb; 27(2):220-8. PubMed ID: 25348594
[TBL] [Abstract][Full Text] [Related]
14. Ineffective esophageal motility: clinical, manometric, and outcome characteristics in patients with and without abnormal esophageal acid exposure.
Shetler KP; Bikhtii S; Triadafilopoulos G
Dis Esophagus; 2017 Jun; 30(6):1-8. PubMed ID: 28475749
[TBL] [Abstract][Full Text] [Related]
15. Survey of findings in patients having persistent heartburn on proton pump inhibitor therapy.
Mandaliya R; DiMarino AJ; Cohen S
Dis Esophagus; 2016 Jan; 29(1):27-33. PubMed ID: 25294046
[TBL] [Abstract][Full Text] [Related]
16. Applying Lyon Consensus criteria in the work-up of patients with proton pump inhibitory-refractory heartburn.
Frazzoni M; Frazzoni L; Ribolsi M; Bortoli N; Tolone S; Russo S; Conigliaro R; Penagini R; Fuccio L; Zagari RM; Savarino E
Aliment Pharmacol Ther; 2022 Jun; 55(11):1423-1430. PubMed ID: 35229321
[TBL] [Abstract][Full Text] [Related]
17. Convenient Method of Measuring Baseline Impedance for Distinguishing Patients with Functional Heartburn from those with Proton Pump Inhibitor-Resistant Endoscopic Negative Reflux Disease.
Yoshimine T; Funaki Y; Kawamura Y; Tamura Y; Izawa S; Ebi M; Ogasawara N; Murotani K; Sasaki M; Kasugai K
Digestion; 2019; 99(2):157-165. PubMed ID: 30179879
[TBL] [Abstract][Full Text] [Related]
18. Ambulatory Reflux Monitoring Guides Proton Pump Inhibitor Discontinuation in Patients With Gastroesophageal Reflux Symptoms: A Clinical Trial.
Yadlapati R; Masihi M; Gyawali CP; Carlson DA; Kahrilas PJ; Nix BD; Jain A; Triggs JR; Vaezi MF; Kia L; Kaizer A; Pandolfino JE
Gastroenterology; 2021 Jan; 160(1):174-182.e1. PubMed ID: 32949568
[TBL] [Abstract][Full Text] [Related]
19. Endoscopic measurement of gastric pH associates with persistent acid reflux in patients treated with proton-pump inhibitors for gastroesophageal reflux disease.
Januszewicz W; Hartley J; Waldock W; Roberts G; Alias B; Hobson A; Wernisch L; di Pietro M
United European Gastroenterol J; 2019 Dec; 7(10):1389-1398. PubMed ID: 31807307
[TBL] [Abstract][Full Text] [Related]
20. Exacerbation of gastroesophageal reflux symptoms after discontinuation of proton pump inhibitors is not associated with increased esophageal acid exposure.
Hoshikawa Y; Nikaki K; Sonmez S; Nakagawa K; Yazaki E; Sifrim D; Woodland P
Neurogastroenterol Motil; 2020 Jan; 32(1):e13735. PubMed ID: 31657519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
